Purified CBD Did Not Significantly Improve Primary Behavior Outcomes in an Autism Trial
A randomized trial in boys with autism and severe behavioral difficulties did not find significant CBD benefits on its primary outcome measures. Improvement in both treatment periods and encouraging caregiver observations did not establish a global treatment effect.
The analyzed sample differed from enrollment
Forty-four boys were randomized, but five could not complete blood collection before receiving treatment. Thirty-nine who received study drug entered the analyses, and 30 completed the full 20-week protocol.
The crossover design compared eight weeks of purified CBD with eight weeks of placebo. CBD was increased from 5 to 20 mg/kg per day. This was a defined purified preparation rather than evidence about all cannabis oils or CBD–THC mixtures.
The primary findings remained null
Primary measures included caregiver-completed behavioral scales and a broader autism assessment. The CBD–placebo contrasts did not reach significance on the primary outcomes.
Some changes, including a larger numerical reduction in repetitive-behavior scores with CBD, appeared promising. However, a numerical difference that does not reach statistical significance cannot be reported as confirmed superiority. Improvement under placebo also made simple before-and-after claims particularly uninformative.
Withdrawals and measurement choices matter
Several participants withdrew, with reasons including caregiver-reported behavioral changes. The smaller completer group should not silently replace the analyzed group, and withdrawal experiences cannot independently prove either treatment benefit or withdrawal causation.
The authors discussed whether broad measures were sufficiently sensitive for this population. That is a limitation and a hypothesis for future trial design, not evidence that the trial necessarily missed a real effect. The findings support further targeted research while preserving the null primary comparison and the population’s specific support needs.
Related: Evaluating CBD treatment comparisons.
Primary research
Cannabidiol (CBD) treatment for severe problem behaviors in boys with autism: A randomized clinical trial. Journal of autism and developmental disorders (2025).
